Abstract
The UN has launched an initiative to place 3 million people in developing countries on antiretroviral AIDS treatment by end 2005 (the 3 by 5 target). Lessons for HIV/AIDS treatment scale-up emerge from recent experience with multidrug-resistant tuberculosis. Expansion of treatment for multidrug-resistant tuberculosis through the multipartner mechanism known as the Green Light Committee (GLC) has enabled gains in areas relevant to 3 by 5, including policy development, drug procurement, rational use of drugs, and the strengthening of health systems. The successes of the GLC and the obstacles it has encountered provide insights for building sustainable HIV/AIDS treatment programmes.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acquired Immunodeficiency Syndrome / drug therapy*
-
Acquired Immunodeficiency Syndrome / prevention & control
-
Anti-Retroviral Agents / economics
-
Anti-Retroviral Agents / supply & distribution
-
Anti-Retroviral Agents / therapeutic use
-
Delivery of Health Care / methods
-
Delivery of Health Care / organization & administration*
-
Drug Costs / statistics & numerical data
-
Drug Industry / economics
-
Drug Industry / methods
-
Financing, Organized / methods
-
Global Health
-
HIV Infections / drug therapy*
-
HIV Infections / prevention & control
-
Health Policy
-
Humans
-
National Health Programs / organization & administration
-
Negotiating / methods
-
Program Development / methods
-
Tuberculosis, Multidrug-Resistant / drug therapy*